SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer
SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- SOTERIA Precision Medicine Foundation, a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ: TEM) to deliver personalized, data-driven cancer treatment insights and advanced genomic sequencing to members of the U.S. active-duty and veteran military populations. The collaboration supports SOTERIA's Cancer Hunt™ initiative, delivering precision oncology patient navigation with Tempus' comprehensive genomic profiling and AI-enabled diagnostic platform to help identify targeted therapies and clinical trial opportunities for active service members and veterans.
Members of the military communities are increasingly being diagnosed with cancer at younger ages and at advanced stages. SOTERIA addresses this critical care gap by providing patient-centric precision oncology navigation and facilitating CLIA-validated germline and somatic sequencing, ensuring that each patient's care is informed by comprehensive molecular data when possible.
"Our mission is to ensure that patients have access to the tools and technology that can inform the most effective treatment path for them," said Julia Civardi, Founder and CEO of SOTERIA. "Partnering with Tempus enables us to bring state-of-the-art genomic sequencing and AI analytics to our active service members and veterans, turning complex molecular data into clear, actionable treatment options for patients and care teams."
"Collaborating with SOTERIA allows us to put cutting-edge genomic insights directly into the hands of clinicians and their patients when every decision matters most," said Ezra Cohen, M.D., Chief Medical Officer of Oncology at Tempus. "We are proud to support SOTERIA's mission and help advance precision oncology for our nation's service members and veterans."
"As a member of the Special Operations community, I've seen the immense toll these cancers take," said CAPT Rob Newson, SEAL, USN (RET), PhD, Chief Community Officer at SOTERIA. "This initiative reflects the best of what's possible when technological innovation and service come together to support our military families."
Through this collaboration, Tempus and SOTERIA will continue to streamline molecular profiling and data integration across SOTERIA's patient cohort, advancing precision oncology research and optimizing care pathways for military community members diagnosed with cancer.
CANCER HUNT INQUIRIES
- Learn more about SOTERIA's Cancer Hunt™ Initiative: https://www.soteriaprecisionmedicine.org/military
- Schedule a consult call with one of SOTERIA's nurse navigators: https://www.soteriaprecisionmedicine.org/book-a-consultation
- Email Contact: support@soteriapmf.org
- Organization Site: https://www.soteriaprecisionmedicine.org
MEDIA CONTACTS
SOTERIA Media Relations
- info@soteriapmf.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/soteria-collaborates-with-tempus-to-advance-precision-oncology-for-us-military-and-veterans-battling-cancer-302933873.html
This press release may not be republished, redistributed, resold or sublicensed without the prior written approval of PR Newswire.
AlphAI analysis
Written by AlphAI from the release above, not by the issuer or PR Newswire. Informational, not investment advice.
The 30-second read
Why it matters
The deal expands Tempus' client base but lacks disclosed financial terms, limiting immediate market impact.
Market read
A modest partnership announcement with limited immediate trading relevance.
What to watch
Potential regulatory or reimbursement hurdles for serving military patients could delay benefits.
Background
Tempus (NASDAQ: TEM) provides AI‑enabled genomic profiling. SOTERIA is a nonprofit focused on cancer care for service members and veterans.
Ticker impact
Tempus announced a new collaboration with SOTERIA to provide genomic sequencing for U.S. military and veteran cancer patients.
potential modest upside as investors price in new military‑veteran market opportunity
Collaboration announcements typically lift sentiment, yet the scale is limited and no financial terms were disclosed.
Market effects
May highlight growing interest in precision oncology within the defense‑health sector.
Limited to U.S. biotech and healthcare investors.
Low, as the collaboration is focused on U.S. military and veteran populations.
Counterpoint
The partnership may not translate into significant revenue without clear pricing or contract size.
Key entities
- companyTempus
NASDAQ‑listed precision oncology data company.
- nonprofitSOTERIA Precision Medicine Foundation
Organization supporting cancer patients in the U.S. military and veteran community.